Last reviewed · How we verify
Intermediate dose dalteparin
Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.
Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Thromboembolism prophylaxis and treatment, Acute coronary syndrome, Venous thromboembolism prevention and treatment.
At a glance
| Generic name | Intermediate dose dalteparin |
|---|---|
| Also known as | dalteparin, Fragmin |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Dalteparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of activated clotting factors, particularly factor Xa and to a lesser extent thrombin. This prevents thrombus formation and propagation. Intermediate dosing provides a balance between anticoagulant efficacy and bleeding risk for specific clinical scenarios.
Approved indications
- Thromboembolism prophylaxis and treatment
- Acute coronary syndrome
- Venous thromboembolism prevention and treatment
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
- Elevated transaminases
Key clinical trials
- The Intensive Care Platform Trial (PHASE4)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration. (NA)
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (PHASE3)
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial (PHASE2)
- inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT (PHASE4)
- TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer (PHASE3)
- Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |